Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Current Leases (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Current Leases for 5 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 6.11% year-over-year to $10.4 million, compared with a TTM value of $10.4 million through Dec 2025, up 6.11%, and an annual FY2025 reading of $9.8 million, up 9.77% over the prior year.
  • Current Leases was $10.4 million for Q4 2025 at Roivant Sciences, up from $9.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $12.3 million in Q1 2021 and bottomed at $9.0 million in Q1 2024.
  • Average Current Leases over 5 years is $10.7 million, with a median of $11.1 million recorded in 2021.
  • The sharpest move saw Current Leases fell 23.32% in 2024, then grew 9.77% in 2025.
  • Year by year, Current Leases stood at $11.2 million in 2021, then rose by 5.53% to $11.9 million in 2022, then fell by 11.68% to $10.5 million in 2023, then dropped by 6.13% to $9.8 million in 2024, then increased by 6.11% to $10.4 million in 2025.
  • Business Quant data shows Current Leases for ROIV at $10.4 million in Q4 2025, $9.0 million in Q3 2025, and $9.4 million in Q2 2025.